COMP <GO>
CAH vs JNJ // EV/EBITDA & P/E VALUATION
Cardinal Health Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CAH 4
— JNJ 11
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $250.48 (-0.24%) • MKT CAP: $58.14B
valuation
24.5x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.70% | 67.90% | -64.20 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.70% | 25.50% | +4.20 | CAH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 24.5x | 18.5x | +6.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.18% | 2.97% | +0.21 | CAH | /fcf-yield <GO> |
| Operating Margin | 1.00% | 34.70% | -33.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.70% | 28.50% | -27.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -1.90% | 6.00% | -7.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.85% | 0.00% | +0.85 | CAH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.59 | -0.43 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.20% | -0.60 | CAH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 60.4 | -1.90 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.08 | -0.18 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.6x | 23.0x | +11.60 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $58.14B | $662.49B | -$604.35B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAH REV | JNJ REV | CAH GROSS % | JNJ GROSS % | CAH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $222.58B | $94.19B | 3.7% | 67.9% | $1.85B | $19.70B |
| FY 2024 | $226.83B | $88.82B | 3.3% | 69.1% | $3.25B | $19.84B |
| FY 2023 | $204.98B | $85.16B | 44.0% | 44.0% | -$6.38B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAH // BETA 0.90
JNJ // BETA 1.08